Assaying kinase activity of the TPL-2/NF-κB1 p105/ABIN-2 complex using an optimal peptide substrate

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Tumour progression locus 2 (TPL-2) is a kinase crucial for tumour necrosis factor alpha (TNFα) production in innate immunity.
• TPL-2 is a potential anti-inflammatory drug target, but previous inhibitors targeting its isolated kinase domain failed clinical development.
• TPL-2 activity regulates macrophage TNF production via association with NF-κB1 p105 and ABIN-2, independent of MKK1/2 phosphorylation.

Purpose of the Study:

• To determine the substrate specificity of the TPL-2/NF-κB1 p105/ABIN-2 complex.
• To compare the inhibitor sensitivities of the TPL-2 complex versus the isolated TPL-2 kinase domain.
• To explore novel therapeutic strategies for anti-inflammatory drug development targeting TPL-2.

Main Methods:

• Utilized a positional scanning peptide library to define optimal substrate specificity for the TPL-2 complex.
• Employed a high-throughput mass spectrometry assay to monitor kinase activity.
• Screened the TPL-2 complex against existing ATP-competitive TPL-2 inhibitors.

Main Results:

• The TPL-2 complex exhibits significantly altered sensitivities to existing ATP-competitive inhibitors compared to the isolated TPL-2 kinase domain.
• The study identified an optimal peptide substrate for the TPL-2 complex.
• These findings suggest a more physiologically relevant approach to TPL-2 inhibitor screening.

Conclusions:

• Screening the TPL-2/NF-κB1 p105/ABIN-2 complex can identify novel chemical series for TPL-2 inhibitors.
• Both ATP-competitive and allosteric inhibitors targeting the complex show promise for anti-inflammatory drug development.
• This approach may overcome limitations of previous TPL-2 inhibitor development efforts.